Bone resorption inhibitor

Alendronate is a potent inhibitor of bone resorption and is most commonly used in the treatment and prevention of osteoporosis.

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

Zoledronic acid (Reclast and Zometa) is a bisphosphonic acid, which is an inhibitor of osteoclastic bone resorption. Zoledronic acid binds to the bone

Bone resorption inhibitors are mainly used to prevent fractures in patients with osteoporosis. By blocking the action of osteoclasts, bone resorption is

There had therefore been an expectation that the responses to a cathepsin K inhibitor might be different from other anti-resorptive drugs, based on the notion that inhibition of cathepsin K may partially uncouple the link between reduction in bone resorption and bone formation, allowing bone formation to continue while bone resorption is

by S Zhou 2024 Cited by 48Currently, the main therapeutic drugs for osteoporosis are bone resorption inhibitors [[115], [116], [117]]. These drugs inhibit bone resorption

Bisphosphonates are inhibitors of bone resorption. They increase bone mineral density by altering osteoclast activation and function. Alendronate and

Subject:Other. Bone resorption inhibitors are drugs that inhibit mineralization or resorption of the bone by blocking the action of osteoclasts.

Another class of bone resorption inhibitors includes bisphosphonates, such as alendronate and zoledronic acid. These drugs bind to bone minerals